Evidence map›Paper›PMID 35078917›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry2022

Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.

Leonidas Chouliaras, Alan Thomas, Maura Malpetti, Paul Donaghy, Joseph Kane, Elijah Mak, George Savulich, Maria A Prats-Sedano, Amanda J Heslegrave, Henrik Zetterberg and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 5 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 5 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Diabetes, hyperglycemia, and ATN blood biomarkers in Hispanic/Latino populations: SOL-INCA study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  18. Article
  19. Review
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Leonidas ChouliarasDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK lc716@medschl.cam.ac.uk.ORCID 0000-0002-3052-3879
Alan ThomasTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Maura MalpettiDepartment of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge, UK.ORCID 0000-0001-8923-9656
Paul DonaghyTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Joseph KaneCentre for Public Health, Queen's University Belfast, Belfast, UK.
Elijah MakDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
George SavulichDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Maria A Prats-SedanoDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Amanda J HeslegraveDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-3930-4354
Li SuDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
James Benedict RoweDepartment of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge, UK.ORCID 0000-0001-7216-8679
John Tiernan O'BrienDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
University of Cambridge · GBNewcastle University · GBQueen's University Belfast · GBSahlgrenska University Hospital · SEUK Dementia Research Institute · GB

Funding

Medical Research Council MR/M009041/1Wellcome Trust 220258
6 · The paper itself

Abstract

objectivesThis longitudinal study compared emerging plasma biomarkers for neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP).

methodsPlasma phosphorylated tau at threonine-181 (p-tau181), amyloid beta (Αβ)42, Aβ40, neurofilament light (NfL) and glial fibrillar acidic protein (GFAP) were measured using highly sensitive single molecule immunoassays (Simoa) in a multicentre cohort of 300 participants (controls=73, amyloid positive mild cognitive impairment (MCI+) and AD dementia=63, LBD=117, FTD=28, PSP=19). LBD participants had known positron emission tomography (PET)-Aβ status.

resultsP-tau181 was elevated in MCI+AD compared with all other groups. Aβ42/40 was lower in MCI+AD compared with controls and FTD. NfL was elevated in all dementias compared with controls while GFAP was elevated in MCI+AD and LBD. Plasma biomarkers could classify between MCI+AD and controls, FTD and PSP with high accuracy but showed limited ability in differentiating MCI+AD from LBD. No differences were detected in the levels of plasma biomarkers when comparing PET-Aβ positive and negative LBD. P-tau181, NfL and GFAP were associated with baseline and longitudinal cognitive decline in a disease specific pattern.

conclusionThis large study shows the role of plasma biomarkers in differentiating patients with different dementias, and at monitoring longitudinal change. We confirm that p-tau181 is elevated in MCI+AD, versus controls, FTD and PSP, but is less accurate in the classification between MCI+AD and LBD or detecting amyloid brain pathology in LBD. NfL was elevated in all dementia groups, while GFAP was elevated in MCI+AD and LBD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionFrontotemporal DementiaLewy Body DiseaseNeurodegenerative DiseasesSupranuclear Palsy, ProgressiveAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic ProteinHumansLongitudinal Studiestau ProteinsAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic Proteintau Proteinsalzheimer's diseasedementiafrontotemporal dementialewy body dementiamovement disorders

Identifiers

PMID35078917
PMCPMC9148982
OpenAlexW4207083026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.